Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.

Ismail NA, Omar SV, Joseph L, Govender N, Blows L, Ismail F, Koornhof H, Dreyer AW, Kaniga K, Ndjeka N.

EBioMedicine. 2018 Feb;28:136-142. doi: 10.1016/j.ebiom.2018.01.005. Epub 2018 Jan 9.

2.
3.

A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.

Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A.

J Clin Microbiol. 2016 Dec;54(12):2956-2962. Epub 2016 Sep 21.

4.

In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis.

Lounis N, Vranckx L, Gevers T, Kaniga K, Andries K.

Med Mal Infect. 2016 Jun;46(4):220-5. doi: 10.1016/j.medmal.2016.04.007.

PMID:
27210281
5.

Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.

Rice DA, Kaniga K, Lee M, Redman R.

Int J Antimicrob Agents. 2013 Apr;41(4):388-92. doi: 10.1016/j.ijantimicag.2012.12.016. Epub 2013 Feb 12.

PMID:
23410792
6.

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.

Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R.

Crit Care. 2012 Nov 13;16(6):R218. doi: 10.1186/cc11862.

7.

In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.

He W, Kaniga K, Lynch AS, Flamm RK, Davies TA.

Diagn Microbiol Infect Dis. 2012 Dec;74(4):417-9. doi: 10.1016/j.diagmicrobio.2012.08.014. Epub 2012 Sep 17.

PMID:
22995366
8.

Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.

Redman R, Damiao R, Kotey P, Kaniga K, Davies T, Naber KG.

J Chemother. 2010 Dec;22(6):384-91.

PMID:
21303745
9.

Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Samtani MN, Flamm R, Kaniga K, Nandy P.

Antimicrob Agents Chemother. 2010 Jun;54(6):2360-4. doi: 10.1128/AAC.01843-09. Epub 2010 Apr 12.

10.

Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.

Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R.

Antimicrob Agents Chemother. 2010 May;54(5):2119-24. doi: 10.1128/AAC.01450-09. Epub 2010 Mar 8.

11.

Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.

Jenkins SG, Fisher AC, Peterson JA, Nicholson SC, Kaniga K.

Curr Med Res Opin. 2009 Dec;25(12):3029-36. doi: 10.1185/03007990903396790.

PMID:
19849650
12.

Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.

Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R.

Antimicrob Agents Chemother. 2009 Sep;53(9):3782-92. doi: 10.1128/AAC.00837-08. Epub 2009 Jul 6.

13.

Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.

Long DD, Aggen JB, Chinn J, Choi SK, Christensen BG, Fatheree PR, Green D, Hegde SS, Judice JK, Kaniga K, Krause KM, Leadbetter M, Linsell MS, Marquess DG, Moran EJ, Nodwell MB, Pace JL, Trapp SG, Turner SD.

J Antibiot (Tokyo). 2008 Oct;61(10):603-14. doi: 10.1038/ja.2008.80.

PMID:
19168974
14.

A multivalent approach to drug discovery for novel antibiotics.

Long DD, Aggen JB, Christensen BG, Judice JK, Hegde SS, Kaniga K, Krause KM, Linsell MS, Moran EJ, Pace JL.

J Antibiot (Tokyo). 2008 Oct;61(10):595-602. doi: 10.1038/ja.2008.79.

PMID:
19168973
15.

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.

Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I.

Clin Ther. 2008 May;30(5):868-83. doi: 10.1016/j.clinthera.2008.04.019.

PMID:
18555934
16.

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.

Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, Prokocimer P, Friedland I.

Curr Med Res Opin. 2008 Jul;24(7):2113-26. doi: 10.1185/03007990802179255 . Epub 2008 Jun 11.

PMID:
18549664
17.

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.

Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I.

Crit Care Med. 2008 Apr;36(4):1089-96. doi: 10.1097/CCM.0b013e3181691b99.

PMID:
18379232
18.

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM.

J Antimicrob Chemother. 2007 Aug;60(2):300-11. Epub 2007 Jun 4.

PMID:
17548456
19.

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS.

J Antimicrob Chemother. 2005 Dec;56(6):1047-52. Epub 2005 Oct 20.

PMID:
16239290
20.

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.

Reyes N, Skinner R, Kaniga K, Krause KM, Shelton J, Obedencio GP, Gough A, Conner M, Hegde SS.

Antimicrob Agents Chemother. 2005 Oct;49(10):4344-6.

21.

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN.

Antimicrob Agents Chemother. 2005 Aug;49(8):3501-12.

22.

In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.

Chen Y, Garber E, Zhao Q, Ge Y, Wikler MA, Kaniga K, Saiman L.

Antimicrob Agents Chemother. 2005 Jun;49(6):2510-1.

23.

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP.

Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34.

24.

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S.

Antimicrob Agents Chemother. 2005 Jan;49(1):195-201.

25.

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Hegde SS, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J, Kaniga K, Pace J, Thomas R, Shaw JP, Obedencio G, Judice JK.

Antimicrob Agents Chemother. 2004 Aug;48(8):3043-50.

27.

In vitro activity of TD-6424 against Staphylococcus aureus.

Pace JL, Krause K, Johnston D, Debabov D, Wu T, Farrington L, Lane C, Higgins DL, Christensen B, Judice JK, Kaniga K.

Antimicrob Agents Chemother. 2003 Nov;47(11):3602-4.

28.
29.

Salmonella spp. are cytotoxic for cultured macrophages.

Chen LM, Kaniga K, Galán JE.

Mol Microbiol. 1996 Sep;21(5):1101-15.

PMID:
8885278
30.

A secreted protein tyrosine phosphatase with modular effector domains in the bacterial pathogen Salmonella typhimurium.

Kaniga K, Uralil J, Bliska JB, Galán JE.

Mol Microbiol. 1996 Aug;21(3):633-41.

PMID:
8866485
32.
33.
34.
35.

Monitoring of Yersinia enterocolitica in murine and bovine feces on the basis of the chromosomally integrated luxAB marker gene.

Kaniga K, Sory MP, Delor I, Saegerman C, Limet JN, Cornelis GR.

Appl Environ Microbiol. 1992 Mar;58(3):1024-6.

37.

ymoA, a Yersinia enterocolitica chromosomal gene modulating the expression of virulence functions.

Cornelis GR, Sluiters C, Delor I, Geib D, Kaniga K, Lambert de Rouvroit C, Sory MP, Vanooteghem JC, Michiels T.

Mol Microbiol. 1991 May;5(5):1023-34.

PMID:
1956283
38.

Supplemental Content

Loading ...
Support Center